Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Trial Profile

Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Registrational
  • Acronyms TIMO
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 25 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jan 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 27 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top